Do you perform the test on circulating tumour cells (CTCs) from blood samples?
The main cells of interest in our analytic platform are CTCs, which are obtained by negative selection and sorting via flow cytometry. You can find further information here [link to site].
Can patients with lymphoma or leukemia have their circulating tumour cell (CTC count measured?
Yes. Patients with lymphoma or leukemia can use an RGCC test to measure their circulating tumour cell count.
Do circulating tumour cells (CTCs) predict the site of relapse and metastases?
Our Metastat test provides this information over a period of three years. It compares profiles of CTCs and metastases to detect relevant markers at the site of relapse.
Why is the circulating tumour cell (CTC) count not indicated in tissue samples?
The tissue sample taken from the tumour during a biopsy is part of the tumour contain cancerous cells, so there is no need to search for CTC populations.
Is it possible to determine from a blood test whether a person will respond to a specific chemotherapeutic agent?
Testing for circulating tumour cells (CTCs) can reveal sensitivity and resistance to several factors. Applying this requires the cooperation and expertise of an oncologist who specialises in pharmacology to schedule dosages, timing and cycles for a patient.
Which is the most comprehensive test?
The Onconomics Plus test provides information about the sensitivity or resistance of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient.
The ChemoSNiP test can be used to predict whether a patient will respond to drugs and metabolise them properly.
Can I include additional substances for testing?
We can include additional natural substances in the Onconomics Plus or Onconomics Extracts tests. Additional chemotherapy drugs can be included in the Onconomics test.
How often do you suggest patients do a follow up test?
This should be determined by your treatment plan.
How often will I need follow-up support tools?
Every three months for the first year, then every six months.
Which cancer cells do you test in an RGCC test?
In any tumour there are several subpopulations of cancer cells, but we only harvest and analyse cells with the tumour-initiating properties.
In which countries are RGCC’s tests approved for use?
Analysis assays cannot be approved. The only test that is approved by the US Food and Drug Administration and the European Medicines Agency is the Cellsearch test. The way we analyse circulating tumour cells is certified for accuracy.
What’s the scientific evidence for the tests RGCC provide?
You can find the data we have published and presented at medical conferences here.